Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.
The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Section 1. Cholinergic drugs for Alzheimer’s disease: Mechanisms, emerging and future evolution1. Introduction
2. Current hypothesis for AD progression
3. Neurotransmitter (NT) systems and peripheral nerve system (PNS)
4. ACh receptors in ACh transmission
5. Choline esterase
6. Cholinergic ACh, AChE, and its inhibitors
7. Classification of ChE inhibitors by binding mode
8. Classification of ChE inhibitors by action mechanism
9. Clinical status of ChE inhibitors
10. AChE inhibitors
11. Forthcoming generation of AChE inhibitors
12. Hybrid inhibitors
13. AChR-targeted drugs for AD treatment
13.1 mAChR muscarinic receptors and antagonists 154
13.2 Semisynthetic and synthetic congeners of ACh antagonists 156
References 158
14. Cholinergic neuromuscular junction and its blocking agents (blockers)
15. Nonadrenergic and noncholinergic (NANC) NTs
16. Protein kinase inhibitors for treatment of AD
17. Inhibition of cholinergic inflammation via AChE inhibitor interaction with ?4?2 nAChR and ?7nAChR, not AChE enzyme inhibition
18. NMDA and non-NMDA receptor antagonism for ADmtreatment
19. Challenges in recent AD therapeutic approaches
20. Identification and application of biomarkers for AD
21 Artificial intelligence (AI)-assisted AD target and drug
discovery
22. Conclusion and perspectives
Section 2. Natural alkaloidal and non-alkaloidal anti-AChE and anti- Alzheimer’s disease compounds in the symptomatic intimation of Alzheimer’s disease
23. Introduction
24. Current bioactive molecules in Alzheimer’s disease therapy
25. Emerging lead compounds from naturally occurring molecules for Alzheimer’s disease therapy
26. Natural antiAChE compounds for Alzheimer’s disease therapy
27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities
28. Conceptual search for MTDs of plant natural compounds for multifactorial Alzheimer’s disease therapy
29. AChE inhibitors in daily consumable cereals and food resources
30. Conclusion and perspective
Section 3. Marine AChE inhibitors for the symptomatic treatment of Alzheimer’s disease
31. Introduction
32. Localization, structure and cellular function of AChE
33. AChE inhibitors from marine resources
34. Non-ChE inhibitory anti-Alzheimer’s disease compounds
35. Emerging concept of dual-target drug (DTD) and multitarget drug (MTD) in AD pathology and promising AD drugs
36. Conclusion and prospectives
Index
Authors
Cheorl-Ho Kim Professor and Chair, Department of Biological Sciences, College of Science, Sungkyunkwan University, South Korea.Dr. Cheorl-Ho Kim is Professor and Chair of the Department of Biological Sciences, College of Science, Sungkyunkwan University in South Korea. He is also Professor at the Samsung Advanced Institute of Health Science and Technology (SAIHST), South Korea. Dr. Kim obtained his MS and PhD from the University of Tokyo, Japan. Prior academic appointments include Genome Program Head, Korea Research Institute of Bioscience and Biotechnology, and Chairman of the Department of Biochemistry and Molecular Biology, Dongguk University, South Korea. Dr. Kim's research interests include neurological health, neuroinflammation, oncogenesis, and cancer metastasis.
